Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase

Expert Rev Cardiovasc Ther. 2013 Aug;11(8):949-57. doi: 10.1586/14779072.2013.814830.


Regenerative therapy in severe heart failure patients presents a challenging set of circumstances including a damaged myocardial environment that accelerates senescence in myocytes and cardiac progenitor cells. Failing myocardium suffers from deterioration of contractile function coupled with impaired regenerative potential that drives the heart toward decompensation. Efficacious regenerative cell therapy for severe heart failure requires disruption of this vicious circle that can be accomplished by alteration of the compromised myocyte phenotype and rejuvenation of progenitor cells. This review focuses upon potential for Pim-1 kinase to mitigate chronic heart failure by improving myocyte quality through preservation of mitochondrial integrity, prevention of hypertrophy and inhibition of apoptosis. In addition, cardiac progenitors engineered with Pim-1 possess enhanced regenerative potential, making Pim-1 an important player in future treatment of severe heart failure.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Cardiomegaly / prevention & control
  • Cell- and Tissue-Based Therapy / methods*
  • Cellular Senescence
  • Genetic Therapy / methods*
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Myocytes, Cardiac / metabolism
  • Proto-Oncogene Proteins c-pim-1 / metabolism
  • Severity of Illness Index
  • Stem Cells / metabolism


  • Proto-Oncogene Proteins c-pim-1